10x Genomics sued Element Biosciences, alleging that Element’s Aviti24 multiomic analysis platform infringes spatial technology patents licensed from Harvard University. The complaint, filed in the U.S. District Court for the District of Delaware, targets multiple U.S. patent numbers tied to spatial analyte detection and a method for selectively sequencing amplicons. 10x is seeking monetary damages, attorneys’ fees, and a permanent injunction. In a statement attributed to Michael Schnall-Levin, 10x said it is taking action to address what it described as infringement of its patented spatial technologies, while an Element spokesperson said the claims lack merit and accused 10x of using the same patent portfolio to stifle innovation. Element said it plans to launch direct in-tissue spatial sequencing products for both fresh-frozen and FFPE tissues on the Aviti24 platform later this year. The dispute follows Element’s broader momentum in spatial sequencing and 10x’s attempts to enforce its licensed IP as spatial systems compete for enterprise and research adoption.